Last reviewed · How we verify
Y-shape pegylated somatropin
At a glance
| Generic name | Y-shape pegylated somatropin |
|---|---|
| Sponsor | Xiamen Amoytop Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children (PHASE2, PHASE3)
- A Trial of YPEG-rhGH in Children With Short Stature (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Y-shape pegylated somatropin CI brief — competitive landscape report
- Y-shape pegylated somatropin updates RSS · CI watch RSS
- Xiamen Amoytop Biotech Co., Ltd. portfolio CI